Lung Cancer, Conjugates Emerge As Key Asia Company Themes

04 Jun 2019

Among Asia Pacific pharma companies presenting new clinical data on their oncology pipelines at ASCO, lung and urothelial cancer and antibody-drug conjugates emerge as stand-out themes.

Multiple Asia-based pharma companies are releasing new clinical data on pipeline oncology assets at the American Society of Clinical Oncology meeting in Chicago, and non-small cell lung cancer (NSCLC) and antibody-drug conjugates (ADCs) are emerging as early themes.

The presentations included some significant results in high-need settings and novel targets.